Table 2.
Primary and secondary outcomes
| Outcomes | Crystalloids (n = 6597) | Combination (n = 920) | Difference (95%CI) |
P | ||
|---|---|---|---|---|---|---|
| Values | 95%CI | Values | 95%CI | |||
| Before PSM | ||||||
| RMST for 28 days (days) | 23.37 | 23.12–23.61 | 25.10 | 24.6–25.6 | 1.73 (1.17–2.29) | < 0.001 |
| RMST for 60 days (days) | 46.09 | 45.31–46.88 | 50.93 | 49.37–52.49 | 4.84 (3.09–6.58) | < 0.001 |
| LOS ICU (days) | 6.65 | 6.47–6.83 | 10.37 | 9.65–11.09 | 3.72 (2.98–4.46) | < 0.001 |
| LOS Hospital (days) | 14.32 | 13.93–14.71 | 19.03 | 18.00–20.07 | 4.72 (3.61–5.82) | < 0.001 |
| Total volume of crystalloids (L) | 2.37 | 2.27–2.41 | 3.11 | 2.84–3.40 | 0.78 (0.49–1.07) | < 0.001 |
| After PSM (1:1) | ||||||
| RMST for 28 days (days) | 22.20 | 21.53–22.86 | 25.10 | 24.60–25.60 | 3.23 (2.38–4.08) | < 0.001 |
| RMST for 60 days (days) | 42.18 | 40.09–44.27 | 50.93 | 49.37–52.49 | 9.09 (6.49–11.69) | < 0.001 |
| LOS ICU (days) | 7.73 | 7.25–8.21 | 10.37 | 9.65–11.08 | 2.64 (1.77–3.50) | < 0.001 |
| LOS Hospital (days) | 15.21 | 14.89–17.44 | 19.04 | 18.00–20.07 | 2.88 (1.24–4.52) | < 0.001 |
| Total volume of crystalloids (L) | 2.76 | 2.46–3.06 | 3.11 | 2.84–3.40 | 0.36 (-0.05–0.77) | 0.085 |
RMST (days) means the restricted mean survival time in each group during the first 28 and 60 days after ICU admission. The difference in RMST (95%CI) was calculated with the difference of restricted mean survival time between the two groups (RMSTcombination-RMSTcrystalloids), which means the increment or reduction of survival owing to the combination therapy. LOS ICU Length of ICU stay, LOS Hospital Length of hospital stay, PSM propensity score matching